AKEELA BENSON: Open Payments
NPI 1679998827 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,780 in 80 payments from 11 companies in 2025. Trend: 2023 $1,078 · 2024 $1,070 · 2025 $5,780
Food & beverage: $3,721Travel & lodging: $2,060
| Company | Payments | Amount |
|---|---|---|
| Janssen Research & Development, LLC | 13 | $1,554 |
| Neurocrine BioSciences, Inc. | 18 | $1,468 |
| Alkermes, Inc. | 12 | $615 |
| Otsuka America Pharmaceutical, Inc. | 3 | $360 |
| Janssen Pharmaceuticals, Inc | 8 | $336 |
| Teva Pharmaceuticals USA, Inc. | 8 | $309 |
| ABBVIE INC. | 6 | $307 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $293 |
| E.R. Squibb & Sons, L.L.C. | 1 | $271 |
| Indivior Inc. | 6 | $142 |
Products named: ARISTADA, INVEGA SUSTENNA, VRAYLAR, CAPLYTA, UZEDY, LYBALVI, ABILIFY MAINTENA, INGREZZA.
Industry payments across CA — which companies pay providers there.
